Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study

被引：0

作者：

Iglesias Docampo, L. ^{[1
]}

Baste Rotllan, N. ^{[2
]}

Oliva Bernal, M. ^{[3
]}

Carral Maseda, A. ^{[4
]}

Perez Segura, P. ^{[5
]}

Medina Colmenero, A. ^{[6
]}

Cirauqui Cirauqui, B. ^{[7
]}

Arrazubi Arrula, V. ^{[8
]}

Martinez Trufero, J. ^{[9
]}

Gutierrez Calderon, V. ^{[10
]}

Garcia Castano, A. ^{[11
]}

Rubio-Casadevall, J. ^{[12
]}

Basterretxea, L. ^{[13
]}

Alvarez Cabellos, R. ^{[14
]}

del Barco Morillo, E. ^{[15
]}

Bruixola, G. ^{[16
]}

Flor, M. J. ^{[17
]}

Assaf Pastrana, J. D. ^{[18
]}

Caballero Daroqui, J. ^{[19
]}

Mesia Nin, R. ^{[20
]}

机构：

[1] Hosp Univ 12 Octubre, Med Oncol, Madrid, Spain

[2] Hosp Clin Barcelona, Med Oncol, Barcelona, Spain

[3] Hosp Duran & Reynals, ICO Inst Catala Oncol Hospitalet, Med Oncol, Lhospitalet De Llobregat, Spain

[4] Hosp Univ Lucus Augusti HULA, Med Oncol, Lugo, Spain

[5] Hosp Clin Univ San Carlos, Med Oncol, IdISSC, Madrid, Spain

[6] Fdn Ctr Oncol Galicia, Med Oncol, La Coruna, Spain

[7] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Barcelona, Spain

[8] Hosp Univ Navarra, Navarra Inst Hlth Res, Med Oncol, IdiSNA, Pamplona, Spain

[9] Hosp Univ Miguel Servet, Med Oncol, Zaragoza, Spain

[10] Hosp Reg Univ Malaga, Med Oncol, Malaga, Spain

[11] Hosp Univ Marques Valdecilla, Med Oncol, Santander, Spain

[12] ICO Girona Inst Catala Oncol Girona, Med Oncol, Girona, Spain

[13] Hosp Univ Donostia, Med Oncol, Donostia San Sebastian, Spain

[14] Hosp Univ Toledo, Med Oncol, Toledo, Spain

[15] Complejo Hosp Salamanca IBSAL, Med Oncol, Salamanca, Spain

[16] Hosp Clin Univ Valencia, Med Oncol, Valencia, Spain

[17] Hosp Univ Virgen Rocio, Med Oncol, Seville, Spain

[18] Hosp Univ Vall dHebron, Med Oncol, Vall dHebron Inst Oncol VHIO, Barcelona, Spain

[19] Hosp Univ & Politecn La Fe, Med Oncol, Valencia, Spain

[20] Hosp Badalona Germans Trias & Pujol, Med Oncol, ICO Inst Catala Oncol Badalona, Badalona, Spain

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.08.932

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

871P

引用

页码：S624 / S624

页数：1

共 50 条

[1] Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.
Iglesias, Lara
Carral, Alberto
Bernal, Marc Oliva
Martinez-Trufero, Javier
Castano, Almudena Garcia
Calderon, Vanesa Gutierrez
Cirauqui, Beatriz
Medina, Ana
Arrazubi, Virginia
Bruixola, Gema
Perez, Pedro
Rotllan, Neus Baste
Alvarez, Ruth
Basterretxea, Laura
Rubio-Casadevall, Jordi
Daroqui, Javier Caballero
Martinez-Galan, Joaquina
Lambea-Sorrosal, Julio Jose
del Barco, Edel
Mesia, Ricard
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[2] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Ji, D.
Sang, Y.
Liu, X.
Guo, Y.
Yang, Y.
Chen, G.
Dong, S.
Wang, Y.
He, X.
Ying, H.
Lu, X.
Wang, Y.
Hu, C.
Ji, Q.
ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
[3] Efficacy and safety of penpulimab plus anlotinib in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): A phase II study
Shi, Y-K.
Gao, L.
Tian, Y.
Chen, J.
Wang, J.
Bai, C.
Li, X.
Su, H.
Liu, Z.
ANNALS OF ONCOLOGY, 2021, 32 : S806 - S806
[4] VCN-01 plus durvalumab in subjects with recurrent/metastatic head & neck squamous cell carcinoma (R/M HNSCC): Phase I clinical trial
Jove, M.
Brana, I.
Taberna, M.
Hernando-Calvo, A.
Brenes Castro, J.
Garralda, E.
Plana Serrahima, M.
Manos Pujol, M.
Capella, G.
Alemany, R.
Blasi, E.
Blasco, C.
Cascallo Piqueras, M.
Nin, R. Mesia
ANNALS OF ONCOLOGY, 2019, 30 : 47 - 47
[5] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Fury, Matthew G.
Sherman, Eric
Ho, Alan
Katabi, Nora
Sima, Camelia
Kelly, Katherine W.
Nwankwo, Oby
Haque, Sofia
Pfister, David G.
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
[6] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
Matthew G. Fury
Eric Sherman
Alan Ho
Nora Katabi
Camelia Sima
Katherine W. Kelly
Oby Nwankwo
Sofia Haque
David G. Pfister
Cancer Chemotherapy and Pharmacology, 2012, 70 : 121 - 128
[7] Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck
Gilbert, Jill
Cmelak, Anthony
Shyr, Yu
Netterville, James
Burkey, Brian B.
Sinard, Robert J.
Yarbrough, Wendall G.
Chung, Christine H.
Aulino, Joseph M.
Murphy, Barbara A.
CANCER, 2008, 113 (01) : 186 - 192
[8] A phase II trial of docetaxel plus cisplatin in recurrent and/or metastatic non-squamous cell carcinoma of head and neck
Imamura, Y.
Kiyota, N.
Tanaka, K.
Hayashi, H.
Ota, I.
Nario, K.
Hirano, S.
Arai, A.
Iwae, S.
Onoe, T.
Minami, S.
Shimada, T.
Yane, K.
Yamazaki, T.
Nagatani, Y.
Toyoda, M.
Otsuki, N.
Nibu, K-I.
Minami, H.
ANNALS OF ONCOLOGY, 2018, 29
[9] Concurrent cetuximab (CTX) and nivolumab (NIVO) in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): Results of phase II study.
Chung, Christine H.
Bonomi, Marcelo Raul
Steuer, Conor Ernst
Schell, Michael J.
Li, Jiannong
Johnson, Matthew
Masannat, Jude
Hernandez-Prera, Juan C.
McMullen, Caitlin
Wadsworth, J.
Patel, Krupal
Kish, Julie Ann
Muzaffar, Jameel
Kirtane, Kedar
Rocco, James William
Saba, Nabil F.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[10] Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head and neck squamous cell carcinoma
Shin, DM
Glisson, BS
Khuri, FR
Ginsberg, L
Papadimitrakopoulou, V
Lee, JJ
Lawhorn, K
Gillenwater, AM
Ang, KK
Clayman, GL
Callender, DL
Hong, WK
Lippman, SM
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) : 1325 - 1330

← 1 2 3 4 5 →